Behind the FDA's AI Push: A Growing Class of Public Healthcare Innovators

USA News Group News Commentary
Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, May 13, 2025 /CNW/ -- USA News Group News Commentary – In a clear sign of growing confidence in artificial intelligence (AI) for healthcare, the U.S. Food and Drug Administration (FDA) has now fully adopted internal AI use, following the successful trial of a generative AI tool designed to streamline scientific review. The system, which helps FDA experts reduce time spent on repetitive tasks, marks a pivotal shift toward automation within regulatory processes. Analysts say this shift further confirms AI's growing role in the future of medicine, with MarketsandMarkets projecting the AI healthcare sector to climb at a 38.6% CAGR, reaching over US$110.61 billion by 2030. As the FDA leans into AI for its own operations, attention is turning to public companies advancing their own healthcare AI platforms—among them Avant Technologies, Inc. (OTC-BB:AVAI), RadNet, Inc. (NASDAQ:RDNT), iCad, Inc. (NASDAQ:ICAD), Microsoft Corporation (NASDAQ:MSFT), and HEALWELL AI Inc. (TSX:AIDX.TO) (OTCQX:HWAIF).